Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018101327) METHOD FOR ESTIMATING GLEASON SCORE OF PROSTATE CANCER, METHOD FOR ESTIMATING PATHOLOGICAL STAGE, AND METHOD FOR ACQUIRING SUPPLEMENTARY INFORMATION, ALL ON THE BASIS OF SPECIFIC PSA CONTENT IN SPECIMEN
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/101327 International Application No.: PCT/JP2017/042802
Publication Date: 07.06.2018 International Filing Date: 29.11.2017
IPC:
G01N 33/574 (2006.01) ,C12Q 1/02 (2006.01) ,G01N 21/64 (2006.01) ,G01N 33/543 (2006.01)
G PHYSICS
01
MEASURING; TESTING
N
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33
Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48
Biological material, e.g. blood, urine; Haemocytometers
50
Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53
Immunoassay; Biospecific binding assay; Materials therefor
574
for cancer
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
Q
MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1
Measuring or testing processes involving enzymes or micro-organisms; Compositions therefor; Processes of preparing such compositions
02
involving viable micro-organisms
G PHYSICS
01
MEASURING; TESTING
N
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
21
Investigating or analysing materials by the use of optical means, i.e. using infra-red, visible, or ultra-violet light
62
Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
63
optically excited
64
Fluorescence; Phosphorescence
G PHYSICS
01
MEASURING; TESTING
N
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33
Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48
Biological material, e.g. blood, urine; Haemocytometers
50
Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53
Immunoassay; Biospecific binding assay; Materials therefor
543
with an insoluble carrier for immobilising immunochemicals
Applicants:
コニカミノルタ株式会社 KONICA MINOLTA, INC. [JP/JP]; 東京都千代田区丸の内二丁目7番2号 2-7-2, Marunouchi, Chiyoda-ku, Tokyo 1007015, JP
国立大学法人弘前大学 HIROSAKI UNIVERSITY [JP/JP]; 青森県弘前市文京町1番地 1, Bunkyouchou, Hirosaki-shi, Aomori 0368560, JP
Inventors:
金子 智典 KANEKO Tomonori; JP
彼谷 高敏 KAYA Takatoshi; JP
大山 力 OHYAMA Chikara; JP
米山 徹 YONEYAMA Tohru; JP
飛澤 悠葵 TOBISAWA Yuki; JP
Agent:
特許業務法人SSINPAT SSINPAT PATENT FIRM; 東京都品川区西五反田七丁目13番6号 五反田山崎ビル6階 Gotanda Yamazaki Bldg. 6F, 13-6, Nishigotanda 7-chome, Shinagawa-ku, Tokyo 1410031, JP
Priority Data:
2016-23132229.11.2016JP
Title (EN) METHOD FOR ESTIMATING GLEASON SCORE OF PROSTATE CANCER, METHOD FOR ESTIMATING PATHOLOGICAL STAGE, AND METHOD FOR ACQUIRING SUPPLEMENTARY INFORMATION, ALL ON THE BASIS OF SPECIFIC PSA CONTENT IN SPECIMEN
(FR) PROCÉDÉ D’ESTIMATION DU SCORE DE GLEASON DU CANCER DE LA PROSTATE, PROCÉDÉ D’ESTIMATION DE CLASSIFICATION DES STADES PATHOLOGIQUES, ET PROCÉDÉ D’ACQUISITION D’INFORMATIONS AUXILIAIRES, SUR LA BASE DE LA TENEUR EN ANTIGÈNE PROSTATIQUE SPÉCIFIQUE DANS UN ÉCHANTILLON
(JA) 検体中の特定のPSAの含有量に基づく、前立腺癌のグリーソンスコアの推定方法、病理病期分類の推定方法、および補助情報の取得方法
Abstract:
(EN) The present invention provides methods that are for acquiring various types of supplementary information used for diagnosis or treatment of prostate cancer, and that can be implemented in a less-invasive manner at a low cost. Provided are, by measuring the contained amount of prostate specific antigen (PSA) having a β-N-acetylgalactosamine residue at a non-reducing terminal of a sugar chain in a specimen, and comparing the measurement with a threshold value: (1) a method for estimating whether a Gleason score (primary pattern and secondary pattern) is less than or not less than a prescribed value, (2) a method for estimating whether the pathological staging (pT) is less than or not less than a prescribed value, and (3) a method for acquiring assessment information indicating diagnosis or treatment should be actively conducted because a GS at full extraction is expected to be higher than a GS at biopsy.
(FR) L’invention fournit un procédé selon lequel sont acquises des informations auxiliaires de différents types destinées au diagnostic ou au traitement du cancer de la prostate, et qui permet un allégement du caractère invasif et une réduction de coût. Selon l’invention, la teneur en APS (antigène prostatique spécifique) présentant un résidu β-N-acétylgalactosamine au niveau d’une terminaison non réductrice d’une chaîne de sucre dans un échantillon, est estimée, et cette valeur d’estimation et une valeur seuil sont comparée. Ainsi, l’invention concerne (1) un procédé selon lequel le score de Gleason (premier type et second type) est estimé supérieur ou égal à une valeur prédéfinie ou inférieure à celle-ci, (2) un procédé selon lequel une classification des stades pathologiques (pT) est estimée supérieure ou égale à une valeur prédéfinie ou inférieure à celle-ci, et (3) un procédé selon lequel sont acquises des informations de jugement relatives à la nécessité de procéder de manière active à un diagnostic ou à un traitement du fait d’une estimation du score de Gleason lors d’une extirpation totale supérieur au score de Gleason lors d’une biopsie.
(JA) 本発明は、低侵襲性かつ低コストで実施することができる、前立腺癌の診断または治療のための各種の補助情報を取得する方法を提供する。 検体中の、β-N-アセチルガラクトサミン残基を糖鎖の非還元末端に有するPSA(Prostate Specific Antigen:前立腺特異抗原)の含有量を測定し、その測定値と閾値とを比較することにより、(1)グリーソンスコア(プライマリーパターンおよびセカンダリーパターン)が所定の値以上または未満であると推定する方法、(2)病理病期分類(pT)が所定の値以上または未満であると推定する方法、および(3)生検時のGSよりも全摘時のGSの方が高いと予想されることから、診断または治療を積極的に行うべきであるとの判断情報を取得する方法である。
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: Japanese (JA)
Filing Language: Japanese (JA)